Making decisions about hormone replacement therapy: Authors' reply

BMJ

Volumn 326, Issue 7403, 2003, Pages 1398-1399

  Rymer, Janice ^a   Wilson, Ruth ^b   Ballard, Karen ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN S UNIVERSITY   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; GONADORELIN;

AGE; BREAST CANCER; CANCER RISK; ESTROGEN THERAPY; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; LETTER; MEDICAL DECISION MAKING; OVARY FUNCTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

DECISION MAKING; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS;

EID: 0037560929     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.326.7403.1398-b     Document Type: Letter

References (5)

1. Erel CT, Elter K, Akman C, Ersavasti G, Altug A, Seyisoglu H, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998; 69: 870–5.
2. Kloosterboer HJ. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol, 1997; 11(suppl 1): 63–68.
3. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone and its metabolites on estrone sulphatose activity in MCG-7 and T-47D mammary cancer cells. Anti Cancer Res 1997; 17: 135–40.
4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effects of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998; 280: 2077–82.
5. Bell NH. Advances in the treatment of osteoporosis. Current drug targets. Curr Drug Targets Immune Endocr Metabol Disord 2001: 1: 93–102.